![Coloplast A/S Website](https://cdn.finchat.io/683131.png)
Coloplast A/S
CPSE-COLO B
Company Overview
Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, it offers voice and respiratory products, including medical devices for neck stoma under the Provox brand; and products for tracheostoma under the TRACOE brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.
Name
Coloplast A/S
CEO
Mr. Kristian Villumsen
Website
www.coloplast.com
Sector
Health Care Equipment and Supplies
Year Founded
1954
Profile
Market Cap
DKK 206.13B
EV
DKK 229.77B
Shares Out
224.84M
Revenue
DKK 26.3B
Employees
16,019
Margins
Gross
67.52%
EBITDA
30.73%
Operating
27.38%
Pre-Tax
24.02%
Net
18.88%
FCF
5.71%
Returns (5Yr Avg)
ROA
23%
ROTA
49.62%
ROE
62.07%
ROCE
57.48%
ROIC
25.96%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
DKK 911.35
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
DKK 887M
Net Debt
DKK 23.64B
Debt/Equity
1.48
EBIT/Interest
9.13
Growth (CAGR)
Rev 3Yr
11.62%
Rev 5Yr
8.42%
Rev 10Yr
8%
Dil EPS 3Yr
1.09%
Dil EPS 5Yr
2.69%
Dil EPS 10Yr
7.52%
Rev Fwd 2Yr
9.28%
EBITDA Fwd 2Yr
10.58%
EPS Fwd 2Yr
9.41%
EPS LT Growth Est
19%
Dividends
Yield
—
Payout
94.97%
DPS
DKK 21
DPS Growth 3Yr
5.27%
DPS Growth 5Yr
13.81%
DPS Growth 10Yr
11.61%
DPS Growth Fwd 2Yr
1.2%